Intensity Modulated Hyperfractionated Accelerated Radiotherapy to Treat Advanced Head and Neck Cancer – Predictive Factors of Overall Survival
Authors:
J. Cvek 1; L. Knybel 1; J. Stránský 2; P. Matoušek 3; O. Res 2; Karol Zeleník 3; B. Otáhal 1; L. Molenda 1; E. Skácelíková 1; N. Stieberová 1; Z. Čermáková 1; D. Feltl 4
Authors‘ workplace:
Klinika onkologická LF OU a FN Ostrava
1; Klinika ústní, čelistní a obličejové chirurgie LF OU a FN Ostrava
2; Klinika otorinolaryngologie a chirurgie hlavy a krku LF OU a FN Ostrava
3; Onkologická klinika 1. LF UK a VFN v Praze
4
Published in:
Klin Onkol 2017; 30(4): 282-288
Category:
Original Articles
doi:
https://doi.org/10.14735/amko2017282
Overview
Aim:
The aim of this study was to evaluate overall survival (OS) and prognostic factors in patients ineligible for chemotherapy who were treated with a hyperfractionated accelerated schedule with simultaneous integrated boost.
Material and Methods:
From May, 2008, to April, 2013, 122 patients with locally advanced nonmetastatic squamous laryngeal (14%), hypopharyngeal (30%), oropharyngeal (30%), and oral cavity (27%) cancer were treated at our institution. The median age, Karnofsky Performance Status (KPS), and gross tumor volume (GTV) of the patients were 63 years (range, 46–87 years), 80% (range, 50–100%), and 46 ml (range, 5–250 ml), resp. The median total dose of radiotherapy was 72.6 Gy (range, 62–77 Gy) at 1.4–1.5 Gy per fraction, and 55 Gy at 1.1 Gy per fraction was delivered for GTV (primary and lymphadenopathy) with a margin of 0.7 cm and regional lymphatic areas with a margin of 0.3 cm. The dose was delivered 2× a day, with a 6–8 hour interval between doses, via a 6 MeV linear accelerator. OS was estimated using the Kaplan-Meier method, and predictors of OS were analyzed using Cox proportional hazards regression.
Results:
The median duration of the radiotherapy series was 37 days (range, 32–45 days). The incidence of grade 3 acute toxicity was 62% for mucosa (oral cavity and/or pharynx) and 0% for skin. Confluent mucositis cleared in all cases within 21 days. No grade 4 or 5 toxicities were recorded. PEG was introduced before treatment in 55 patients (45%). The 1-and 2-year OS was 65% and 32%, resp. KPS less than 80% (RR 2.4, 95% CI 1.3–4.2; p = 0.004), cancers other than oropharyngeal or laryngeal cancer (RR 2.0, 95% CI 1.1–3.5; p = 0.016), and capacity of high GTV (RR 1.006, 95% CI 1.001–1.011; p = 0.017) were found to be negative prognostic factors for OS. Conclusion: More than 30% of patients with poor prognosis survived for longer than 2 years. KPS before treatment was the strongest prognostic factor for better OS.
Key words:
head and neck cancer – radiotherapy dose fractionation – survival analysis – acceleration – hyperfractionation
This work was supported by RVO-FNOs/2016 (HPV status as predictive and prognostic factor for primary and secondary head and neck cancer).
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
9. 3. 2017
Accepted:
19. 4. 2017
Sources
1. Pignon JP, Bourhis J, Domenge CO et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355 (9208): 949–955.
2. Corvò R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007; 85 (1): 156–170.
3. Bourhis J, Overgaard J, Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368 (9538): 843–854.
4. Mohan R, Wu Q, Manning M et al. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000; 46 (3): 619–630.
5. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48 (1): 7–16.
6. Overgaard J, Hansen HS, Specht L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362 (9388): 933–940.
7. Skladowski K, Maciejewski B, Golen M et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 2006; 66 (3): 706–713.
8. Terhaard CH, Kal HB, Hordijk GJ. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in week 3. Int J Radiat Oncol Biol Phys 2005; 62 (1): 62–69.
9. Halámka M, Feltl D, Cvek J et al. Projekt HARDROCK: parametrický sběr a analýza dat pacientů s nádory hlavy a krku na Klinice onkologické FN Ostrava – důraz na význam frakcionace a definice cílového objemu v radioterapii. Klin Onkol 2012; 25 (4): 274–281.
10. Strongin A, Yovino S, Taylor R et al. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012; 82 (5): 1823–1830. doi: 10.1016/j.ijrobp.2010.10.053.
11. Tsou YA, Hua JH, Lin MH et al. Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer – does tumor volume correlate with central necrosis and tumor pathology? ORL J Otorhinolaryngol Relat Spec 2006; 68 (4): 206–212.
12. Chung EJ, Lee NJ, Baek SK et al. Clinical efficacy of primary tumor volume measurements: comparison of different primary sites. Clin Exp Otorhinolaryngol 2009; 2 (2): 78–84.
13. Johnson CR, Thames HD, Huang DT et al. The tumor voluem and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys 1995; 33 (2): 281–287.
14. Siddiqui F, Pajak TF, Watkins-Bruner D et al. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys 2008; 70 (2): 353–360.
15. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363 (1): 24–35. doi: 10.1056/NEJMoa0912217.
16. Hoffman HT, Porter K, Karnell LH et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116 (2 Suppl 111): 1–13.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2017 Issue 4
Most read in this issue
- Reactive Lymphoid Hyperplasia of the Liver
- Metastatic Pituitary Disorders
- Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis
- Radiation Necrosis in the Upper Cervical Spinal Cord in a Patient Treated with Proton Therapy after Radical Resection of the Fourth Ventricle Ependymoma